Document:

Plain English Warrant, dated October 7, 2008

 Exhibit 4.3(D) 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 AS AMENDED (the “1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY, IN FORM AND SUBSTANCE, TO YOU THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 PLAIN ENGLISH WARRANT 
 This is a PLAIN ENGLISH WARRANT dated October 7,
2008 by and between ONCOMED PHARAMCEUTICALS, INC. a Delaware corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company. 
 The words “We”, “Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is
ONCOMED PHARMACEUTICALS, INC., and not to any individual. The words “The Parties” refers to both TRIPLEPOINT CAPITAL LLC and ONCOMED PHARAMCEUTICALS, INC. This Plain English Warrant may be referred to as the “Warrant”.

 The Parties have entered into a Plain English Master Lease Agreement dated as of January 12, 2007, and related Software or Hardware
Facility Schedules and Summary Schedules, and that certain letter agreement dated September 11, 2008, which are collectively referred to as the “Lease Agreement”. 
 In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below: 

 

					
	WARRANT INFORMATION
			
	 Effective Date
	 	 Warrant Number
	 	 Lease Facility Schedules

			
	October 7, 2008	 	461-W-04	 	0461-LE-02H
			
	  	 	Warrant Coverage	 	  
	  
 $45,000 (4.5% of
$1,000,000)
 The Warrant Coverage is subject to adjustment as set forth in Section 1.

			
	 Number of Shares
	 	 Price Per Share
	 	 Type of Stock

			
	Warrant Coverage divided by Exercise Price	 	As set forth in Section 1 of this Warrant under the caption “What You Agree to Grant Us.”	 	Series B Preferred Stock or Next Round Preferred Stock, pursuant to Section 1 of this Warrant
	
	OUR CONTACT INFORMATION
			
	 Name
	 	 Address For Notices
	 	 Contact Person

	TriplePoint Capital LLC	 	 2755 Sand Hill Road, Ste. 150
 Menlo Park, CA 94025
 Tel: (650) 854-2090

Fax: (650) 854-2094
	 	 Sajal Srivastava, COO
 Tel: (650) 233-2102
 Fax: (650) 854-2094

email: sks@triplepointcapital.com

	
	YOUR CONTACT INFORMATION
			
	 Customer Name
	 	 Address For Notices
	 	 Contact Person

	Oncomed Pharmaceuticals, Inc.	 	 800 Chesapeake Drive
 Redwood City, CA, 94063
	 	 Paul Hastings, CEO
 Tel: (650) 995-8200
 Fax: (650) 298-8600

email: paul.hastings@oncomed.com

  
 1 

  

	1.	WHAT YOU AGREE TO GRANT US. 

  

You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant, to subscribe to and to purchase from You that
number of fully paid and non-assessable shares of Applicable Preferred Stock equal to the quotient of (a) Forty Five Thousand Dollars ($45,000) divided by (b) the Exercise Price (as defined below). 

For purposes of this Warrant, the “Applicable Preferred Stock” shall be Your Series B Preferred Stock, par value $0.001 per share (the
“Series B Preferred”); provided, however, that in the event the price per share of the Next Round Preferred Stock (as defined below) paid by investors in the Next Round (as defined below) is lower than the original price per share of Your
Series B Preferred Stock (i.e., $1.40 per share), the “Applicable Preferred Stock” from and after the closing of the Next Round shall be the Next Round Preferred Stock. 
 For purposes of this Warrant, “Next Round” shall mean the next round of equity financing subsequent to the Effective Date in which at least a total of $10,000,000 of cash proceeds are received
from investors, including without limitation an equity financing involving the sale and issuance of Your Series B-1 Preferred Stock. 
 For
purposes of this Warrant, the “Next Round Preferred Stock” shall mean the series of Preferred Stock, par value $0.001 per share, which You issue in the Next Round. For the avoidance of doubt, the Next Round Preferred Stock shall include a
round of equity financing involving the sale and issuance of Your Series B-1 Preferred Stock. 
 The Exercise Price shall be the lesser of:
(i) $1.40 per share (i.e., the original price per share of Your Series B Preferred Stock) and (ii) the price per share of the Next Round Preferred Stock paid by investors in the Next Round. 

The number and purchase price of such shares are subject to adjustment as provided in Section 4 hereof. 

The Parties agree that this Warrant to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as
part of the leased value and will be allocable to the Warrant and the original issue discount on the Lease Agreement shall be considered to be zero. 
  

 

	2.	WHEN ARE WE ENTITLED TO PURCHASE YOUR APPLICABLE PREFERRED STOCK. 

 
 The term of this Warrant and our right to purchase
Applicable Preferred Stock will begin on the Effective Date, and shall be available for the greater of: (i) 7 years from the Effective Date, (ii) 5 years from the effective date of Your initial public offering of Your Common Stock pursuant
to a registration statement under the 1933 Act (“Your IPO”). 
 Notwithstanding the foregoing, Our right to purchase the Warrant Stock
shall be automatically and fully exercised (without surrender of the Warrant) upon the occurrence of a Merger Event (as defined below in Section 4), in which You are not the surviving corporation, provided that, upon consummation of the Merger
Event, the consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) cash or (ii) cash and/ or stock that is traded on a recognized public exchange or on the NASDAQ Stock Market at a price
per share equal to or greater than two (2) times the Exercise Price per share (as adjusted). No less than ten (10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with
a copy of the proposed merger agreement and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of the executed merger
agreement, (b) any other documents in connection therewith, (c) information concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably necessary to an informed
evaluation of Our rights under this Agreement. 
 In such a Merger Event, if the consideration payable to Us pursuant to the exercise of this
Warrant and on account of the Warrant Stock upon the occurrence of a Merger Event does not consist of (i) cash or (ii) cash and/or stock that is traded on a recognized public exchange or on the NASDAQ Stock Market or is less than two
(2) times the Exercise Price per share and We have not elected to exercise Our rights under this Warrant, then You may, at Your sole discretion, pay Us a sum equal to one (1) time the Exercise Price for each share exercisable under this
Warrant in exchange for the cancellation of this Warrant upon the consummation of the Merger Event. 

  
 2 

  

	3.	HOW WE MAY PURCHASE YOUR APPLICABLE PREFERRED STOCK. 

 
 We may exercise Our purchase rights, in whole or in
part, at any time, or from time to time, prior to the expiration of the term of this Warrant, by (i) surrender of the Warrant to be held in escrow by You until receipt of the Applicable Preferred Stock by Us, together with a completed and
executed Notice of Exercise in the form attached as Exhibit I, to Your principal offices and (ii) unless We elect the Net Issuance Method pursuant to the Notice of Exercise, payment to You of an amount equal to the aggregate
Exercise Price for the number of shares being purchased. 
 Promptly upon receipt of the Notice of Exercise and in any event no later than
twenty-one (21) days after you have received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Applicable Preferred Stock that We have
purchased and You will execute the Acknowledgment of Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any. 

We may pay for the Applicable Preferred Stock by either (i) cash, check or wire transfer (to an account designated by You), or (ii) by the
net issuance method as determined below. If We elect the Net Issuance method, You will issue Applicable Preferred Stock using the following formula: 
  

					
		  		  	 X = Y(A-B)

		  		  	            A
	Where:	  	X =	  	the number of shares of Applicable Preferred Stock to be issued to Us.
		  	Y =	  	the number of shares of Applicable Preferred Stock We request to be exercised under this Warrant.
		  	A =	  	the fair market value of one share of Applicable Preferred Stock.
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Applicable Preferred Stock shall mean with respect to
each share of Applicable Preferred Stock: 
 If the exercise is in connection with the initial public offering of Your Common Stock, and
if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” specified in the final prospectus
of the offering and (y) the number of shares of Common Stock into which each share of Applicable Preferred Stock is convertible at the time of such exercise; 
 If this Warrant is exercised after, and not in connection with Your initial public offering, and: 
  

	•	 	 if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five
(5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Applicable Preferred Stock is convertible at
the time of such exercise; or 

  

	•	 	 if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked
prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock
into which each share of Applicable Preferred Stock is convertible at the time of such exercise; 

  

	•	 	 if at any time Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market,
the current fair market value of Applicable Preferred Stock shall be the product of (x) the fair market value of a share of Your Common Stock, as determined in good faith by Your Board of Directors and (y) the number of shares of Common
Stock into which each share of Applicable Preferred Stock is convertible at the time of such exercise, unless You shall become subject to a Merger Event pursuant to which You are not the surviving party, in which case the fair market value of
Applicable Preferred Stock shall 

  
 3 

	 	 
be deemed to be the value received by the holders of Your Applicable Preferred Stock on a Common Stock-equivalent basis pursuant to such Merger Event. 

 

	•	 	 During the term of this Warrant, You will at all times from and after the Effective Date have authorized and reserved a sufficient number
of shares of (a) Applicable Preferred Stock to provide for the exercise of our rights to purchase Applicable Preferred Stock, and (b) Common Stock to provide for the conversion of the Applicable Preferred Stock.

 If We elect to exercise part of the Warrant, You will promptly issue to Us an amended Warrant stating the remaining number
of shares that are available. All other terms and conditions of that amended Warrant shall be identical to those contained in this Warrant. 

If at the end of the term of this Warrant, the fair market value of one share of Warrant Stock (or other security issuable upon the exercise hereof) as
determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of Warrant Stock (or such other
securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion to Us. 

 
  

	4.	WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE. 

 
  

	•	 	 If You are Acquired. Subject to the termination provisions in Section 2 above, if at any time (i) there is a
reorganization of Your stock (other than a reclassification, exchange or subdivision of Your stock otherwise provided for in this Warrant), (ii) You merge or consolidate with or into another entity whether or not You are the surviving entity,
(iii) You sell or convey, or grant an exclusive license with respect to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of
fifty percent (50%) or more of the outstanding voting power of the capital stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall be made so that
We shall thereafter be entitled to receive, upon exercise of Our rights under this Warrant, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that
which would have been issuable if We had exercised Our rights under this Warrant immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Your Board of Directors) shall be made in the
application of the provisions of this Warrant with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant (including adjustments of the Exercise Price and number of shares of Applicable Preferred Stock
purchasable) shall be applicable to the greatest extent possible. 

  

	•	 	 If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change
any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant will thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, subdivision or other
change. 

  

	•	 	 If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Applicable Preferred Stock, the Exercise
Price will be proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination. 

  

	•	 	 If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution
specifically provided for in the above paragraphs) of Your stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in effect
immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of which shall be
the total number of all shares of Your stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the 

  
 4 

	 	 
Exercise Price resulting from such adjustment, the number of shares of Applicable Preferred Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect
immediately prior to such adjustment by the number of shares of Applicable Preferred Stock issuable upon the exercise hereof immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment.

  

	•	 	 If You Change the Antidilution Rights of the Applicable Preferred Stock or Your Certificate of Incorporation. All antidilution
rights applicable to the Series B Preferred purchasable under this Warrant are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification or
waiver of Your Certificate of Incorporation. 

  
  

	5.	WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT. 

 
 Subject to the terms and conditions contained in
Section 7, We (or any successor transferee) may transfer in whole or in part this Warrant and all its rights. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our
payment of all transfer taxes and other governmental charges involved in such transfer. So long as You have not assigned Your assets for the benefit of Your creditors, have entered (voluntarily or involuntarily) a bankruptcy proceeding, liquidated
or taken any action for the purpose of the foregoing, You may refuse to transfer this Warrant or any Applicable Preferred Stock to any person who directly competes with You (as determined in good faith by You) unless Your stock is publicly traded.

  
  

	6.	REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU. 

 
  

	•	 	 Reservation of Applicable Preferred Stock. The Applicable Preferred Stock issuable upon exercise of Our rights under this Warrant
will be duly and validly reserved and when issued in accordance with the provisions of this Warrant will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever;
provided, however, that the Applicable Preferred Stock issuable pursuant to this Warrant may be subject to restrictions on transfer under state and/or Federal securities laws. 

 

	•	 	 Due Authority. Your execution and delivery of this Warrant and the performance of Your obligations hereunder, including the
issuance to Us of the right to acquire the shares of Applicable Preferred Stock, have been duly authorized by all necessary corporate action on Your part and this Warrant is not inconsistent with the Your Certificate of Incorporation or Bylaws, does
not contravene any law or governmental rule, regulation or order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by
which You are bound, and this Warrant constitutes a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the
rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies. 

  

	•	 	 Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of
any state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant, except for the filing of any required notices pursuant to Federal and state
securities laws, which filings will be effective by the times required thereby. 

  

	•	 	 Issued Securities. All of Your issued and outstanding shares of Common Stock, Applicable Preferred Stock or any other securities
have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and Applicable Preferred Stock were issued in full compliance with all Federal and state securities laws. In addition, as of
the Effective Date: 

  

	 	•	 	 Your authorized capital consists of (A) 142,675,102 shares of Class A Common Stock, of which 5,142,713 shares are issued and outstanding,
(B) 44,440 shares of Class B Common Stock, of which all 

  
 5 

	 	 
shares are issued and outstanding, (C) 18,000,000 shares of Series A Preferred Stock, of which 17,776,000 shares are issued and outstanding, (D) 285,714 shares of Series X Preferred
Stock, none of which are issued and outstanding, (E) 31,874,999 shares of Series B Preferred Stock, of which 30,803,570 shares are issued and outstanding, (F) 61,605,525 shares of Series B-1 Preferred Stock, of which 25,367,648 are issued
and outstanding, (G) 8,215,962 shares of Series B-2 Preferred Stock of which 6,647,058 are issued and outstanding. 

  

	 	•	 	 You have reserved 11,300,000 shares of Common Stock, under which (i) 3,342,733 shares of Class A Common Stock have been issued pursuant to
restricted stock purchase agreements and/or the exercise of outstanding options and (ii) options to purchase 5,241,964 shares of Class A Common Stock have been granted and are currently outstanding, and (iii) 2,715,303 shares of
Class A Common Stock remain available for future issuance to officers, directors and employees of the Company pursuant to the Company’s Stock Incentive Plan, as amended. Except as otherwise provided in this Warrant and as noted above, and
except for (a) Warrants to Purchase Stock issued to Silicon Valley Bank to purchase an aggregate of 70,048 shares of Series A Preferred Stock, (b) the Warrant to Purchase Preferred Stock issued to Kwacker Limited to purchase an aggregate
of 55,000 shares of Series B Preferred Stock and (c) the Plain English Warrants issued to Us (subject to adjustment on the terms and conditions provided for therein), there are no other options, warrants, conversion privileges or other rights
presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Your capital stock or other of Your securities. 

  

	 	•	 	 Except as set forth in Your Investor Rights Agreement, Your shareholders do not have preemptive rights to purchase new issuances of Your capital stock.

  

	•	 	 Other Commitments to Register Securities. Except as set forth in Your Investor Rights Agreement, You are not, pursuant to the
terms of any other agreement currently in existence, under any obligation to register under the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued. 

 

	•	 	 Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Applicable
Preferred Stock upon exercise of this Warrant will constitute a transaction exempt from (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Regulation D thereof, and (ii) the qualification requirements of
the applicable state securities laws. 

  

	•	 	 Compliance with Rule 144. We may sell the Applicable Preferred Stock issuable hereunder in compliance with Rule 144 promulgated by
the Securities and Exchange Commission. Within ten (10) business days of Our request, You agree to furnish Us, a written statement confirming Your compliance, to the extent applicable, with the filing requirements of the Securities and Exchange
Commission as set forth in such Rule 144, as may be amended. 

  

	•	 	 Tax Covenants. Upon Our exercise of this Warrant, You will issue to Us certificates for shares of Applicable Preferred Stock
without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Applicable Preferred Stock. You will not be required to pay any tax, which may be payable in respect of any transfer
involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC. 

  

 

	7.	OUR REPRESENTATIONS AND COVENANTS TO YOU. 

 
  

	•	 	 Investment Purpose. The right to acquire Applicable Preferred Stock or the Applicable Preferred Stock issuable upon exercise of
Our rights contained herein and the Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any
public distribution of the same except pursuant to a registration under the 1933 Act or an exemption therefrom. 

  
 6 

	•	 	 Private Issue. We understand (i) that this Warrant, the Applicable Preferred Stock issuable upon exercise of this Warrant and
the Common Stock issuable upon conversion of the Applicable Preferred Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from
the registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7. 

 

	•	 	 Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Applicable Preferred Stock
issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Applicable Preferred Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to
be bound in writing to the applicable terms and conditions of this Warrant, and (iii) if You request, We shall have furnished You with an opinion of counsel in form and substance satisfactory to You and Your counsel to the effect that
(A) appropriate action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the
transferability of any of Our rights to acquire Applicable Preferred Stock issuable upon exercise of such rights or the Common Stock issuable upon conversion of the Applicable Preferred Stock do not apply to transfers from the beneficial owner of
any of the aforementioned securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Applicable Preferred Stock when (1) such security shall have been effectively registered under
the 1933 Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You
at Our request by the staff of the Securities and Exchange Commission (the “SEC”) or a ruling shall have been issued to the You at Our request by the SEC stating that no action shall be recommended by such staff or taken by the SEC, as the
case may be, if such security is transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required.
Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the holder of a share of Applicable Preferred Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without
expense to such holder, one or more new certificates for the Warrant or for such shares of Applicable Preferred Stock not bearing any restrictive legend referring to 1933 Act registration or exemption. 

 

	•	 	 Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and
financial condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment. 

 

	•	 	 Risk of No Registration. We understand that if You do not register with the SEC pursuant to Section 12 of the 1934 Act (the
“1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to purchase Applicable
Preferred Stock pursuant to this Warrant, or (ii) the Applicable Preferred Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Applicable Preferred Stock, We may be required to
hold such securities for an indefinite period. We also understand that any sale of Our right to purchase Applicable Preferred Stock or Applicable Preferred Stock or Common Stock issuable upon conversion of the Applicable Preferred Stock, which might
be made by it in reliance upon Rule 144 under the 1933 Act may be made only in accordance with the terms and conditions of that Rule. 

  

	•	 	 Accredited Investor. We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of
Regulation D, as presently in effect. 

  

	•	 	 Market Stand-Off. In connection with Your IPO and upon request of You or the underwriters managing such offering of Your
securities, We agree not to sell, make any short sale of, loan, pledge or otherwise hypothecate or encumber, grant any option for the purchase of, enter into any hedging or similar transaction with the same economic effect as a sale, or otherwise
dispose of any of Your securities (other than any disposed of in the registration and those acquired by Us in the registration or thereafter in open market transactions) without the prior written consent of You or such managing underwriters, as the
case may be, for such period of time (not to exceed one hundred eighty (180) days from the effective date of such registration) as may be requested by You or such managing underwriters and to execute an agreement reflecting the

  
 7 

	 	 
foregoing as may be requested by the underwriters at the time of Your IPO. You may impose stock-transfer instructions and may stamp each such certificate with a legend with respect to the shares
of Common Stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day period. We agree to execute a market standoff agreement with said underwriters in customary form consistent with the
provisions hereof. Notwithstanding the foregoing, We agree that the 180-day period may be extended for up to such number of additional days as is deemed necessary by You or the managing underwriters to continue coverage by research analysts in
accordance with NASD Rule 2711 or any successor rule. 

  

 

	8.	NOTICES YOU AGREE TO PROVIDE US. 

  

You agree to give Us at least twenty (20) days prior written notice before the effective date of any of the following events: 

 

	•	 	 If You Pay a dividend or distribution declaration upon your stock. 

 

	•	 	 If You offer for subscription pro-rata to the existing shareholders additional stock or other rights. 

 

	•	 	 If You consummate a Merger Event. 

  

	•	 	 If You consummate Your IPO. 

  

	•	 	 If You dissolve or liquidate. 

 All notices in this Section must set forth details of the event, how the event adjusts either Our number of shares or Our Exercise Price and the method used for such adjustment. 

Timely Notice. Your failure to timely provide such notice required above shall entitle Us to retain the benefit of the applicable notice period
notwithstanding anything to the contrary contained in any insufficient notice received by Us. 
  

 

	9.	DOCUMENTS YOU WILL PROVIDE US. 

  

 

	•	 	 Certified Resolutions of Your Board of Directors authorizing this Warrant 

 
  

	10.	OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY. 

 
 Effective Date. This Warrant shall be
construed and shall be given effect in all respects as if it had been executed and delivered by the Parties on the date hereof. This Warrant shall be binding upon any of the successors or assigns of the Parties. 

Attorney’s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant, the prevailing party shall
be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant. 
 Governing Law. This
Warrant shall be governed by and construed for all purposes under and in accordance with the laws of the State of California without giving effect to that body of law pertaining to conflicts of laws. 

Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Warrant may be brought in any state or federal
court of competent jurisdiction located in the State of California. By execution and delivery of this agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California;
(b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound
by any judgment rendered thereby in connection with this Plain English Warrant. Service of process on any party hereto in any action arising out of or relating to this agreement shall be 

  
 8 

 
effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall affect the right
to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert
person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT
THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU.
IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE
CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED
BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES.
THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES
ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You
and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant. 
 Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 Notices. Any notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively given upon the
earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via
confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending party, in any case addressed as follows: 
 If to TriplePoint Capital LLC, to Our “Contact Person” designated on the cover page at a specified “Address for Notices,” with a copy to: 

If to OncoMed Pharmaceuticals, Inc., to Your “Contact Person” designated on the cover page at a specified “Address for Notices,” with
a copy to: 
 Latham & Watkins LLP 
 140 Scott Drive 
 Menlo Park, CA 94025 
 Tel: 650-328-4600 
 Fax: 650-463-2600 
 Attention: Mark V. Roeder 
 Remedies. In the event of any default hereunder, the
non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for
any default where such party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant and that in
the event of any breach 

  
 9 

 
of this Agreement, the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such
breach of this Agreement. 
 No Impairment of Rights. You will not, by amendment of your Charter or through any other means, avoid or
seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to
protect Our rights against impairment. 
 Survival. The representations, warranties, covenants, and conditions of the Parties contained
herein or made pursuant to this Warrant shall survive the execution and delivery of this Warrant. 
 Severability. In the event any one
or more of the provisions of this Warrant shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a
mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 Entire Agreement. This Warrant constitutes the entire agreement between the Parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements,
representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. 
 Amendments. Any
provision of this Warrant may only be amended by a written instrument signed by the Parties. 
 Lost Warrants or Stock Certificates. You
covenant to Us that, upon receipt of evidence reasonably satisfactory to You of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to You, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, You will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen,
destroyed or mutilated Warrant or stock certificate. 
 Rights as Stockholders. We shall not, as a party to this Warrant, be entitled to
vote or receive dividends or be deemed the holder of Series B Preferred Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon
Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until this Warrant
is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
 Facsimile
Signatures. This Warrant may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

[Signature Page to Follow] 

  
 10 

 IN WITNESS WHEREOF, each of the Parties have caused this Plain English Warrant to be executed by its
officers who are duly authorized as of the Effective Date. 
  

							
	 YOU:
	 		 	ONCOMED PHARMACEUTICALS, INC.
				
		 		 	By:	 	 /s/    William D.
Waddill        

				
		 		 	Title:	 	 SENIOR VICE PRESIDENT

		 		 		 	CHIEF FINANCIAL OFFICER
			
	 US:
	 		 	TRIPLEPOINT CAPITAL LLC
				
		 		 	By:	 	 /s/    Sajal
Srivastava        

				
		 		 	Title:	 	 COO

 [SIGNATURE PAGE TO PLAIN ENGLISH WARRANT AGREEMENT 0461-W-04] 

  
 11 

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	                           
              

  

	1.	We hereby elect to purchase              shares of Your Series     
Preferred Stock, pursuant to the terms of the Plain English Warrant dated the      day of                     ,
200     (the “Plain English Warrant”) between You and Us, and hereby tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.

  

	2.	Method of Exercise (Please initial the applicable blank) 

  

	 	a.	             We elect to exercise the Plain English Warrant by means of a cash payment, and gives You full
payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

  

	 	b.	             We elect to exercise the Plain English Warrant by means of the Net Issuance Exercise method of
Section 3 of the Plain English Warrant. 

  

	3.	In exercising Our rights to purchase Your Series      Preferred Stock, We hereby confirm and acknowledge the investment representations,
warranties and covenants made in Section 7 of the Plain English Warrant. 

 Please issue a certificate or certificates
representing these purchased shares of Series      Preferred Stock in Our name or in such other name as is specified below. 
  

			
	  

	(Name)
	
	  

	(Address)
		
	US:	 	TRIPLEPOINT CAPITAL LLC
		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  

  
 12 

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 

                         
               , hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase
             shares of the Series      Preferred Stock of
                    , pursuant to the terms of the Plain English Warrant, and further acknowledges that
             shares remain subject to purchase under the terms of the Plain English Warrant. 
  

							
	 YOU:
	 		 	  

				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 13 

 EXHIBIT III 
 TRANSFER NOTICE 
 FOR VALUE RECEIVED, the foregoing Plain English Warrant and all
rights evidenced thereby are hereby transferred and assigned to 
  

					
	  
	 	
	(Please Print)	 		 	

					
		
	Whose address is	 	  

	
	  

 

					
	Dated:	 	  
	 	
			
	Holder’s Signature:	 	  
	 	
			
	Holder’s Address:	 	  
	 	
			
	Transferee’s Signature:	 	  
	 	
			
	Transferee’s Address:	 	  
	 	
			
	Signature Guaranteed:	 	  
	 	

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Plain
English Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should present to OncoMed Pharmaceuticals, Inc. proper evidence of authority to
assign the foregoing Plain English Warrant. 

  
 14Amended and Restated Investor Rights Agreement

 Exhibit 4.4(A) 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This Amended and
Restated Investor Rights Agreement (the “Agreement”) is made as of October 7, 2008, by and among OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the stockholders listed
on Exhibit A hereto (individually an “Investor” and collectively the “Investors”). 
 RECITALS 
 A. The Company and certain of the Investors (the
“Existing Investors”) are parties to that certain Amended and Restated Investor Rights Agreement, dated December 7, 2007 (the “Prior Agreement”). 

B. The Company and certain of the Investors have entered into a Series B-1 Preferred and Series B-3 Preferred Stock Purchase
Agreement (the “Purchase Agreement”) of even date herewith pursuant to which the Company wants to sell to certain of the Investors, and certain of the Investors want to purchase from the Company, shares of the Company’s
Series B-1 Preferred Stock, and pursuant to which the Company wants to sell to SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania corporation (“GSK”), and GSK wants to purchase from the Company, shares
of the Company’s Series B-3 Preferred Stock. 
 C. The Company and the Existing Investors desire to induce the
Investors to purchase shares of Series B-1 Preferred Stock and to induce GSK to purchase shares of Series B-3 Preferred Stock pursuant to the Purchase Agreement by agreeing to amend and restate the Prior Agreement in its entirety and provide
the Investors with certain rights to register shares of the Company’s Common Stock issuable upon conversion of the Preferred Stock held by such Investors, certain rights to receive information pertaining to the Company, and a right of first
offer with respect to certain issuances by the Company of its securities. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows: 
  

	 	1.	Restrictions on Transferability; Registration Rights 

 1.1 Certain Definitions. As used in this Agreement, the following terms have the following respective meanings: 
 “Board” or “Board of Directors” means the board of directors of the Company. 
 “Commission” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 

 “Common Stock” means, collectively, the Class A Common Stock
and Class B Common Stock of the Company or any other Common Stock of the Company into which such Class A Common Stock or Class B Common Stock converts. 
 “Convertible Securities” means any bonds, debentures, notes or other evidences of indebtedness, options, warrants, shares (including, but not limited to, shares of Series A
Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series B-3 Preferred Stock of the Company) or any other securities convertible into, exercisable for, or exchangeable for Common Stock. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar successor federal statute
and the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 “Form S-3
Initiating Holders” means any Holder or Holders who in the aggregate hold not less than twenty percent (20%) of the Registrable Securities then outstanding and who propose to register securities, the aggregate offering price of
which, net of underwriting discounts and commissions, exceeds $1,000,000. 
 “Holder” means (i) any
Investor holding Registrable Securities and (ii) any person holding Registrable Securities to whom the rights under this Agreement have been duly and validly transferred in accordance with Section 1.11 hereof. For purposes of
Section 1.4 and Section 1.5 and, solely to the extent necessary to provide registration rights under such Sections 1.4 and 1.5 and to cause Silicon Valley Bank (“Lender”) to be entitled to the rights and subject to
the obligations under Sections 1.4 through 1.10, 1.12 and 1.14 of the Agreement, the term “Holder” shall include Lender. 
 “Initiating Holders” means any Holder or Holders who in the aggregate hold not less than thirty-five percent (35%) of the Registrable Securities then outstanding and who
propose to register securities the aggregate proceeds of which (after deduction for underwriter’s discounts and expenses related to issuance) exceed $15,000,000. 
 “IPO” means the first public offering of the Common Stock of the Company to the general public that is effected pursuant to a registration statement filed with, and declared
effective by, the Commission under the Securities Act. 
 “New Securities” means any shares of capital
stock of the Company, including Common Stock and Preferred Stock, whether authorized or not, and rights, options, or warrants to purchase said shares of capital stock, and securities of any type whatsoever that are, or may become, convertible into
capital stock; provided, however, that the term “New Securities” does not include: 
 (A) The issuance
of any Common Stock or Convertible Securities (and the Common Stock issued upon exercise or conversion thereof) as a dividend on the Company’s capital stock. 

  
 2 

 (B) The issuance of shares of, or options to purchase shares of, Common Stock (and the
Common Stock issued upon exercise of such options) to employees, consultants or directors pursuant to stock purchase or stock option plans or any other arrangement approved by the Board of Directors, including a majority of the Preferred Directors,
as defined in the Company’s Amended and Restated Certificate of Incorporation (“Restated Certificate”). Such shares of Common Stock issued pursuant to this subsection shall be adjusted for any subdivisions and
combinations and shall include shares repurchased by the Company and any cancellation or expiration of options to purchase these shares. 
 (C) The issuance of shares of Common Stock or Convertible Securities (and the Common Stock issued upon conversion and/or exercise thereof) to lenders, financial institutions or equipment lessors in
connection with equipment financing arrangements approved by the Board of Directors. 
 (D) The issuance of Common Stock or
Convertible Securities pursuant to the acquisition of another entity by the Company by merger, purchase of substantially all of the assets or shares, or other reorganization whereby the Company or its stockholders own not less than a majority of the
voting power of the surviving or successor entity, or the acquisition of technology or other intellectual property by outright purchase or exclusive license, in each case as approved by the Board of Directors. 

(E) The issuance of shares of Common Stock issued upon conversion of shares of Preferred Stock in accordance with the Restated
Certificate. 
 (F) The issuance of shares of Series B Preferred Stock and Series B-1 Preferred Stock pursuant to the terms of
the Series B Purchase Agreement, as may be amended from time to time by its terms (and the Common Stock issued upon conversion thereof). 
 (G) The issuance of shares of Series B-1 Preferred Stock and shares of Series B-3 Preferred Stock pursuant to the terms of the Purchase Agreement, as may be amended from time to time by its terms (and the
Common Stock issued upon conversion thereof). 
 (H) The issuance of shares of Common Stock issued in a registered public
offering under the Securities Act. 
 (I) All shares of Common Stock and Convertible Securities outstanding as of the date of
this Agreement. 
 “Other Shares” means shares of Common Stock, other than Registrable Securities (as
defined below) (including shares of Common Stock issuable upon conversion of shares of any currently unissued series of Preferred Stock of the Company) with respect to which registration rights have been granted. 

  
 3 

 “Other Stockholders” means persons other than Holders who, by virtue
of agreements with the Company, are entitled to include their Other Shares in certain registrations hereunder. 

“Preferred Stock” means, collectively, the Series A Preferred Stock, Series B Preferred Stock, Series B-1
Preferred Stock, Series B-2 Preferred Stock and Series B-3 Preferred Stock of the Company or any other Common Stock of the Company into which such Series A Preferred Stock, Series B Preferred Stock, or Series B-1 Preferred Stock, Series B-2
Preferred Stock or Series B-3 Preferred Stock converts. 
 “Pro Rata Portion” means the ratio that
(x) the sum of the number of shares of the Company’s Common Stock held by a Investor immediately prior to the issuance of New Securities, assuming full conversion of the Shares then held by such Investor into the Company’s Common
Stock, bears to (y) the sum of the total number of shares of the Company’s Common Stock then outstanding, assuming full conversion into the Company’s Common Stock of all Shares then outstanding. 

The terms “register”, “registered” and “registration” refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 

“Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 1.3, 1.4
and 1.5 hereof, including, without limitation, all registration, qualification, listing and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company fees and disbursements for one counsel for the Investors, blue
sky fees and expenses, and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company), but shall not include
Selling Expenses or fees and disbursements of counsel for the Holders. 
 “Registrable Securities” shall
mean (i) shares of Common Stock issued or issuable pursuant to the conversion of the Shares and (ii) any Common Stock of the Company issued as a dividend or other distribution with respect to or in exchange for or in replacement of the
shares referenced in clause (i) above; provided, however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or
dealer or underwriter in a public distribution or a public securities transaction, (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all
transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale, (C) transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with
Section 1.11 hereof, or (D) with respect to each Holder, all such shares held by such Holder become eligible for sale under Rule 144 of the Securities Act (or any similar or successor rule) during any one 90-day period. For purposes
of Section 1.4 and Section 1.5 and, solely to the extent necessary to provide registration rights under Sections 1.4 and 1.5 and to cause Lender to be entitled to the rights and subject to the obligations under Sections 1.4 through 1.10,
1.12 and 1.14 of the Agreement, the term “Registrable Securities” shall include 

  
 4 

 
shares of Common Stock issued or issuable pursuant to the shares of Series A Preferred Stock issued or issuable pursuant to the exercise of the Warrant to Purchase Shares of Stock issued on or
about October 14, 2004 to Lender (the “Warrant”). 
 “Restricted Securities” shall mean
the securities of the Company required to bear the legend set forth in Section 1.2 hereof. 
 “Rule
144” means Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

“Rule 145” means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended
from time to time, or any similar successor rule that may be promulgated by the Commission. 
 “Securities
Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder or any similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect
at the time. 
 “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock
transfer taxes applicable to the securities registered by the Holders. 
 “Shares” means, collectively,
the Company’s Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series B-3 Preferred Stock. 
  

	 	1.2	Restrictions. 

(a) Subject to Section 1.11, each Holder agrees not to make any disposition of all or any portion of Shares or Registrable
Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this Section 1.2 and Section 1.13, provided and to the extent such Sections are then applicable, and (i) there is then in
effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement, or (ii) such Holder shall have notified the Company of the proposed
disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and, if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of
counsel, reasonably satisfactory to the Company, that such disposition will not require registration under the Securities Act. Notwithstanding the foregoing, no such registration statement or opinion of counsel shall be necessary for a transfer to
an affiliate of a Holder or by a Holder which is (A) a partnership to its partners or former or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former members in accordance with
their interest in the limited liability company, or (C) to the Holder’s family member or trust for the benefit of an individual Holder, provided in the case of a transfer to an affiliate and all cases enumerated in clauses (A) –
(C) that the transferee is subject to the terms of this Section 1.2 and Section 1.13 as if such transferee were an original Holder hereunder. Each 

  
 5 

 
Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer
established in this Section 1.2. 
 (b) Each certificate representing Shares or Registrable Securities shall be stamped or
otherwise imprinted with legends substantially in the following forms (in addition to any legend required under applicable state securities laws, the Company’s charter documents or any other agreement between the Company and the Holder
thereof): 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, TRANSFERRED, OR PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL OR OTHER EVIDENCE SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS
OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 (c)
The Company shall promptly reissue unlegended certificates at the request of any Holder thereof if the Holder shall have obtained an opinion of counsel reasonably acceptable to the Company to the effect that the securities proposed to be disposed of
may lawfully be disposed of without registration, qualification or legend. 
  

	 	1.3	Requested Registration. 

 (a) Request for Registration. If the Company shall receive from Initiating Holders a written request that the Company effect any registration, qualification or compliance, the Company will:

 (i) promptly deliver written notice of the proposed registration, qualification, or compliance to all other Holders; and

 (ii) as soon as practicable, use its best efforts to effect such registration, qualification or compliance (including,
without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws, and appropriate compliance with applicable regulations issued under the
Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a 

  
 6 

 
written request delivered to the Company within twenty (20) days after delivery of such written notice from the Company; provided, however, that the Company shall not be
obligated to take any action to effect any such registration, qualification, or compliance pursuant to this Section 1.3: 
 (A) Prior to the earlier of: (i) five (5) years following the date of this Agreement, and (ii) six (6) months following the effective date of the IPO; 

(B) After the Company has effected two (2) such registrations pursuant to this Section 1.3, such registrations
have been declared or ordered effective and the securities offered pursuant to such registrations have been sold; 
 (C) During the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on a date one hundred eighty (180) days after the effective date
of, a registration initiated by the Company; provided that the Company is actively employing in good faith reasonable efforts to cause such registration statement to become effective and that the Company’s estimate of the date of
filing such registration statement is made in good faith in a certificate signed by the President of the Company; 
 (D) In any particular jurisdiction in which the Company would be required to qualify to do business or execute a general consent to service of process in effecting such registration, qualification or
compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; or 
 (E) If in the good faith judgment of the Board, such registration would be seriously detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such
registration statement at such time, and the Company thereafter delivers to the Initiating Holders a certificate, signed by the President or Chief Executive Officer of the Company, stating that in the good faith judgment of the Board it would be
detrimental to the Company or its stockholders for a registration statement to be filed in the near future, then the Company’s obligation to use its best efforts to register, qualify or comply under this Section 1.3 shall be deferred for a
period not to exceed ninety (90) days from the delivery of the written request from the Initiating Holders; 

(F) If the Initiating Holders do not request that such offering be firmly underwritten by underwriters selected by the
Initiating Holders (subject to the consent of the Company, which consent will not be unreasonably withheld); or 

(G) If the Initiating Holders propose to dispose of shares of Registrable Securities which may be immediately registered
on Form S-3 pursuant to a request made under Section 1.4 hereof. 

  
 7 

 Subject to the foregoing clauses (A) through (G), the Company shall file a registration statement
covering the Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. The registration statement filed pursuant to the request of the Initiating Holders may,
subject to the provisions of Sections 1.3(c) and Section 1.2 hereof, include other securities of the Company with respect to which registration rights have been granted, and may include securities being sold for the account of the Company.

 (b) Underwriting. The right of any Holder to registration pursuant to this Section 1.3 shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. A Holder may elect to include in such underwriting all or a part
of the Registrable Securities held by such Holder. 
 (c) Procedures. If the Company shall request inclusion in
any registration pursuant to this Section 1.3 of securities being sold for its own account, or if other persons shall request inclusion in any registration pursuant to this Section 1.3, the Initiating Holders shall, on behalf of all
Holders, offer to include such securities in the underwriting and may condition such offer on their acceptance of the applicable provisions of this Section 1. The Company shall (together with all Holders or other persons proposing to distribute
their securities through such underwriting) enter into and perform its obligations under an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders
(which managing underwriter shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 1.3, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a
limitation of the number of shares to be underwritten, the number of shares to be included in the underwriting or registration shall be allocated as set forth in Section 1.12. If any person who has requested inclusion in such registration as
provided above disapproves of the terms of the underwriting, such person shall be excluded therefrom by written notice delivered by the Company or the managing underwriter. Any Registrable Securities and/or other securities so excluded or withdrawn
shall also be withdrawn from registration. 
  

	 	1.4	Registration on Form S-3. 

 (a) Qualification on Form S-3. After the IPO, the Company shall use best efforts to qualify for registration on Form S-3 or any comparable or successor form. To that end the Company
shall register (whether or not required by law to do so) its Common Stock under the Exchange Act in accordance with the provisions of the Exchange Act following the effective date of the first registration of any securities of the Company on Form
S-1 or any comparable or successor form or forms. 
 (b) Request for Registration on Form S-3. After the Company
has qualified for the use of Form S-3, if the Company shall receive from Form S-3 Initiating Holders a written request that the Company effect a registration on Form S-3 the Company will: 

  
 8 

 (i) promptly deliver written notice of the proposed registration to all other Holders;
and 
 (ii) as soon as practicable, use best efforts to effect such registration, qualification or compliance (including,
without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws, and appropriate compliance with applicable regulations issued under the
Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request delivered to the Company within twenty (20) days after delivery of such written notice from
the Company; provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 1.4: 

(A) If the Company has effected two (2) registrations on Form S-3 pursuant to this Section 1.4 during the
preceding twelve-month period; 
 (B) The condition in Section 1.3(a)(ii)(C) has been met; 

(C) The condition in Section 1.3(a)(ii)(D) has been met; 

(D) The condition in Section 1.3(a)(ii)(E) has been met; or 

(E) If Form S-3 is not available for such offering by the Holders. 

(c) Underwriting; Procedure. If a registration requested under this Section 1.4 is for an underwritten offering, the
provisions of Sections 1.3(b) and 1.3(c) shall apply to such registration. 
 (d) S-3’s not Demands.
Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant to Section 1.3. 
  

	 	1.5	Company Registration. 

 (a) Notice of Registration. If the Company shall determine to register any of its securities, either for its own account or the account of a security holder or holders other than (A) a
registration pursuant to Sections 1.3 or 1.4 hereof, (B) a registration relating solely to employee benefit plans, (C) a registration relating solely to a Rule 145 transaction or (D) a registration on any registration form that does
not permit secondary sales, the Company will: 

  
 9 

 (i) deliver to each Holder written notice thereof within thirty (30) days after such
determination; and 
 (ii) use best efforts to include in such registration (and any related qualification under blue sky laws
or other compliance), except as set forth in Section 1.5(b) below, and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made by any Holder and delivered to the Company within ten
days after the written notice is delivered by the Company. Such written request may include all or a portion of a Holder’s Registrable Securities. 
 (b) Underwriting; Procedures. If the registration of which the Company gives notice pursuant to Section 1.5(a)(i) is for a registered public offering involving an underwriting, the
Company shall so advise the Holders as a part of such notice. In such event, the right of any Holder to registration pursuant to this Section 1.5 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion
of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through
such underwriting) enter into and perform their obligations under an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 1.5,
if the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may exclude all Registrable Securities from, or limit the number of Registrable Securities to be
included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be
allocated as set forth in Section 1.12. If any person who has requested inclusion in such registration as provided above disapproves of the terms of the underwriting, such person shall be excluded therefrom by written notice delivered by the
Company or the managing underwriter. Any Registrable Securities and/or other securities so excluded or withdrawn shall also be withdrawn from registration. 
 (c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.5 prior to the effectiveness of such
registration, whether or not any Holder has elected to include securities in such registration. 
 1.6 Registration
Procedures. In the case of each registration, qualification, or compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration,
qualification, and compliance and as to the completion thereof and, at its expense, the Company will use reasonable best efforts to: 
 (a) Prepare and file with the Commission a registration statement with respect to such securities and use best efforts to cause such registration statement to become and remain effective for up to ninety
(90) days or, if earlier, until the distribution described in the registration statement has been completed; provided, however, that (i) such 90-day period shall 

  
 10 

 
be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of common stock or other
securities of the Company, and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such 90-day period shall be extended, if necessary, to up to 180 days
provided that if Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that if applicable rules under the Securities Act governing the obligation to file a post-effective
amendment permit, in lieu of filing a post-effective amendment which (A) includes any prospectus required by Section 10(a)(3) of the Securities Act or (B) reflects facts or events representing a material or fundamental change in the
information set forth in the registration statement, the incorporation by reference of information required to be included in (A) and (B) above shall be contained in periodic reports filed pursuant to Section 13 or 15(d) of the
Exchange Act in the registration statement; 
 (b) Furnish to the Holders participating in such registration and to the
underwriters of the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus, final prospectus, and such other documents as such underwriters may reasonably request in order to facilitate the
public offering of such securities; 
 (c) Prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection with such registration statements as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement; 
 (d) Notify each seller of Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing, and at the request of any such seller, prepare and furnish
to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchaser of such shares, such prospectus shall not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing; 

(e) Use best efforts to register and qualify the securities covered by such registration statement under such other securities or blue
sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of
process in any such states or jurisdictions; 
 (f) Cause all such Registrable Securities to be listed on each securities
exchange on which similar securities issued by the Company are then listed; 

  
 11 

 (g) Provide a transfer agent and registrar for all Registrable Securities and a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; and 
 (h) Use best
efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a
registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes
effective, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the
underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter, dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by
independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities (to the extent the then-applicable standards of
professional conduct permit said letter to be addressed to the Holders). 
 1.7 Information by Holder. The Holder
or Holders of Registrable Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them, and the distribution proposed by such Holder or Holders as the
Company may request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this Section 1, and the refusal to furnish such information by any Holder or Holders shall relieve the
Company of its obligations in this Section 1 with respect to such Holder or Holders. Furthermore, the Company shall have no obligation with respect to any registration requested pursuant to Section 1.3 or Section 1.4 of this Agreement
if, as a result of the application of the preceding sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the
anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in the definition of “Initiating Holders” or “Form S-3 Initiating Holders,” whichever is
applicable. 
  

	 	1.8	Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors, partners,
members, legal counsel and accountants, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification, or compliance has been effected pursuant to this
Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or liabilities (or actions, proceedings or
settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular, or other document

  
 12 

 
(including any related registration statement, notification, or the like), or any amendment or supplement thereto, incident to any such registration, qualification, or compliance, (ii) any
omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or (iii) any violation by the
Company of the Securities Act or any rule or regulation promulgated under the Securities Act applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of
its officers, directors, partners, legal counsel and accountants, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in
connection with investigating, preparing, defending or settling any such claim, loss, damage, liability or action, as such expenses are incurred, provided that the Company will not be liable in any such case to the extent that any such claim, loss,
damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by such Holder, any of such
Holder’s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls and such underwriter and stated to be specifically for use therein. The Company shall not be
required to indemnify any person against any liability arising out of the failure of any Holder or any person acting on behalf of a Holder to deliver a prospectus as required by the Securities Act. It is agreed that the indemnity agreement contained
in this Section 1.8 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld).

 (b) To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the
securities as to which such registration, qualification, or compliance is being effected, indemnify the Company, each of its directors, officers, partners, members, legal counsel and accountants, and each underwriter, if any, of the Company’s
securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder and Other Stockholder, each of their officers,
directors, members, and partners and each person controlling such Holder or Other Stockholder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising
out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular, or other document, or (ii) any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, Other Stockholders, directors, officers, partners, legal counsel and
accountants, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, as such expenses are incurred, in each
case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in
conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein, provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such
claims, losses, damages or 

  
 13 

 
liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided further that in no
event shall any indemnity under this Section 1.8 exceed the gross proceeds received by such Holder in such offering. 
 (c)
Each party entitled to indemnification under this Section 1.8 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after
such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the
Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such
party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.8 unless the failure to give such notice is
materially prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment
or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party
shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom.

 (d) If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any claim, loss, damage, liability or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such claim, loss, damage, liability or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and the Indemnified party on the other in
connection with the statements or omissions that resulted in such claim, loss, damage, liability, or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact related to information supplied by the Indemnifying Party or by the Indemnified Party and the
parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The Company and the Holders agree that it would not be just and equitable if contribution pursuant to this
Section 1.8 were based solely upon the number of entities from whom contribution was requested or by any other method of allocation which does not take account of the equitable considerations referred to above. In no event shall any
contribution by a Holder under this Section 1.8 exceed the gross proceeds received by such Holder in such offering. 
 (e)
The amount paid or payable by an Indemnified Party as a result of the losses, claims, damages, and liabilities referred to above in this Section 1.8 shall be deemed 

  
 14 

 
to include any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim, subject to the provisions of
Section 1.8(c). No person guilty of fraudulent misrepresentation (within the meaning of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

(f) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(g) The obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable
Securities in a registration statement. 
 1.9 Expenses of Registration. All Registration Expenses incurred in
connection with any registration effected pursuant to Sections 1.3, 1.4 or 1.5 and reasonable fees (up to a maximum of $40,000) for one counsel for the selling Holders shall be borne by the Company; provided, however, that if the
Holders bear the Registration Expenses for any registration proceeding begun pursuant to Section 1.3 and subsequently withdrawn by the Holders registering shares therein, such registration proceeding shall not be counted as a requested
registration pursuant to Section 1.3. Furthermore, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is different from the information known or available (upon request from the
Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section 1.3, such registration proceeding shall not be counted as a requested registration pursuant to Section 1.3, even
though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of the registered securities included in such registration
pro rata on the basis of the number of shares so registered. 
 1.10 Rule 144 Reporting. With a view to
making available to the Holders the benefits of certain rules and regulations of the Commission which may permit the sale of the Restricted Securities to the public without registration after such time as a public market exists for the Common Stock
of the Company, the Company agrees to use best efforts to: 
 (a) Make and keep public information available, as those terms are
understood and defined in Rule 144, at all times after the effective date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 

(b) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements); and 

  
 15 

 (c) So long as a Holder owns any Restricted Securities, to furnish to the Holder forthwith
upon request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of any other reporting requirements of the Securities Act and the Exchange Act (at any time after it has become subject to such
reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as a Holder may
reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 
 1.11 Transfer of Registration Rights. The rights to cause the Company to register securities granted to any party hereto under Section 1 may be assigned by a Holder only to a transferee
or assignee of not less than 250,000 shares of Registrable Securities (as appropriately adjusted for stock splits and the like) held by such Holder, or, in the case of Nomura European Investment Limited (“Nomura”), by Nomura
to any of its Affiliates (as defined in Section 4.2) or to a fund managed by any of such Affiliates, provided that the Company is given written notice at the time of or within a reasonable time after said assignment, stating the name and
address of the transferee or assignee and identifying the securities with respect to which such registration rights are being assigned, and, provided further, that the assignee of such rights assumes in writing the obligations of such
Holder under this Section 1. Notwithstanding the foregoing, no such minimum share assignment requirement shall be necessary for an assignment to an affiliate of a Holder or by a Holder which is (A) a partnership to its partners or former
or retired partners in accordance with partnership interests, (B) a limited liability company to its members or former or retired members in accordance with their interest in the limited liability company, or (C) to the Holder’s
family member or trust for the benefit of an individual Holder. 
 1.12 Procedure for Underwriter Cutbacks. In any
circumstance in which all of the Registrable Securities and Other Shares requested to be included in a registration on behalf of Holders and Other Stockholders, respectively, cannot be so included as a result of limitations of the aggregate number
of shares of Registrable Securities and Other Shares that may be so included, the number of shares of Registrable Securities and Other Shares that may be so included shall be allocated among the Holders and Other Stockholders requesting inclusion of
shares pro rata based upon the total number of Registrable Securities or Other Shares held by such Holders and Other Stockholders, respectively; provided, however, that such allocation shall not operate to reduce the aggregate number
of Registrable Securities or Other Shares to be included in such registration if any Holder or Other Stockholder does not request inclusion of the maximum number of shares of Registrable Securities or Other Shares allocated to such Holder or Other
Stockholder pursuant to the above-described procedure, in which case the remaining portion of his allocation shall be reallocated among those requesting Holders and Other Stockholders whose allocations did not satisfy their requests pro rata on the
basis of total number of shares of Registrable Securities and Other Shares held by such Holders and Other Stockholders, and this procedure shall be repeated until all shares of Registrable Securities and Other Shares which may be included in the
registration on behalf of the Holders and Other Stockholders have been so allocated. Notwithstanding anything else set forth herein or in any other agreement, the Company shall not limit the number of Registrable Shares to be included in

  
 16 

 
a registration pursuant to this Agreement in order to include Other Shares, or in the case of registrations pursuant to Section 1.3 or 1.4 hereof, in order to include in such registration
securities registered for the Company’s own account. 
 1.13 Standoff Agreement. In connection with the IPO
and upon request of the Company or the underwriters managing such offering of the Company’s securities, each Holder hereby agrees not to sell, make any short sale of, loan, pledge or otherwise hypothecate or encumber, grant any option for the
purchase of, enter into any hedging or similar transaction with the same economic effect as a sale, or otherwise dispose of any securities of the Company (other than any disposed of in the registration and those acquired by the Holder in the
registration or thereafter in open market transactions) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days from the effective date of such registration as may be
requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the IPO. The Company may impose stop-transfer instructions and may stamp each such
certificate with the second legend set forth in this Section 1.13 with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day period. Each Holder
agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this Section 1.13 provided that (x) all officers and directors of the Company then holding Common Stock of the Company
and (y) all stockholders holding in the aggregate at least 1% of the total equity of the Company, enter into similar agreements. Notwithstanding the foregoing, the 180-day period may be extended for up to such number of additional days as is
deemed necessary by the Company or the managing underwriter to continue coverage by research analysts in accordance with FINRA Rule 2711 or any successor rule. The parties agreed that said underwriters are the intended third-party beneficiaries of
this Section 1.13. 
 1.14 Termination of Rights. The rights of any particular Holder to cause the Company to
register securities under Sections 1.3, 1.4 and 1.5 shall terminate with respect to such Holder upon the earlier of (i) five (5) years following the consummation of the IPO, or (ii) when such Holder can sell all of its
Registrable Securities within a three (3)-month period pursuant to Rule 144, without reference to Rule 144(k). 
 1.15
Limitations of Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least sixty-six and two-thirds percent (66 2/3%) of the outstanding
Registrable Securities held by the Investors, not including those shares of Registrable Securities held by GSK, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or
prospective holder (a) to include such securities in any registration filed under Section 1 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to
the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration which could result in such registration statement being declared
effective prior to the earlier of either of the dates set forth in Section 1.3(a) or within one hundred twenty (120) days after the effective date of any registration effected pursuant to Section 1.3; provided, for the
avoidance of doubt, that the Registrable Securities held 

  
 17 

 
by GSK shall not be factored into the numerator or denominator used to calculate the percentage required for written consent pursuant to this Section 1.15. 

 

	 	2.	Right of First Refusal 

  

	 	2.1	Right of First Refusal. 

 (a) Right of First Refusal. Subject to the terms and conditions contained in this Section 2.1, the Company hereby grants to each Preemptive Rights Investor (as defined below) the right
of first refusal to purchase (on the same terms and conditions and at the same price) such Preemptive Rights Investor’s Pro Rata Portion of any New Securities which the Company may, from time to time, propose to issue and sell. For the purposes
of this Agreement, “Preemptive Rights Investor” means each Investor who holds not less than 1,400,000 shares of Registrable Securities (as adjusted for stock splits, combinations, reorganizations and the like). 

(b) Notice of Right. The Company shall give written notice of the proposed issuance of New Securities to each Preemptive
Rights Investor not later than twenty (20) days prior to issuance. Such notice shall contain all material terms and conditions of the issuance and of the New Securities. Each Preemptive Rights Investor may elect to exercise all or any portion
of its rights under this Section 2.1 by giving written notice to the Company within fifteen (15) days after the Company’s notice stating therein the quantity of New Securities such Preemptive Rights Investor intends to purchase. If
the consideration paid by others for the New Securities is not cash, the value of the consideration shall be determined in good faith by the Board of Directors, and any electing Preemptive Rights Investor that cannot for any reason pay for the New
Securities in the form of non-cash consideration may pay the cash equivalent thereof, as determined by the Board of Directors. Each Preemptive Rights Investor shall have a right of overallotment such that, if any other Preemptive Rights Investor
fails to exercise the right to purchase its full Pro Rata Portion of the New Securities, the other participating Preemptive Rights Investor may, before the date ten (10) days following the expiration of the fifteen (15) day period set
forth above, exercise an additional right to purchase, on a pro rata basis, the New Securities not previously purchased by so notifying the Company, in writing, within such ten (10) day period. Subject to compliance with applicable securities
laws, each Preemptive Rights Investor shall be entitled to apportion New Securities to be purchased among its partners and affiliates, provided that such Preemptive Rights Investor notifies the Company in writing of such allocation. 

(c) Lapse and Reinstatement of Right. The Company shall have ninety (90) days following the periods described in
Section 2.1(b) to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within thirty (30) days from the date of said agreement) to sell the New Securities with respect to
which the Investors’ right of first refusal was not exercised, at a price and upon terms no more favorable to the purchasers of such securities than specified in the Company’s notice. In the event the Company has not sold the New
Securities or entered into an agreement to sell the New Securities within said ninety (90) day period (or sold and issued New Securities in accordance with the foregoing within thirty (30) days from the date of said agreement), the Company
shall 

  
 18 

 
not thereafter issue or sell any New Securities without first offering such securities to the Investors in the manner provided above. 

2.2 Assignment of Right of First Refusal. The right of first refusal granted hereunder may not be assigned or transferred,
except that such right is assignable (a) by each Investor to any wholly-owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Securities Act, controlling, controlled by, or under common control with,
any such Investor or, in the case of Nomura, to any of the related entities defined in Section 4.2; or (b) between and among any Investors. 
 2.2 Termination of Right of First Refusal. The right of first refusal granted under Section 2.1 of this Agreement shall expire immediately prior to the earlier of: (a) the
consummation of the Company’s IPO; (b) the acquisition of the Company by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger, or consolidation), provided that the
Company’s stockholders of record as constituted immediately prior to such transaction hold less than 50% of the voting power of the surviving or acquiring entity; or (c) sale or other conveyance of all or substantially all of the assets of
the Company to an unaffiliated entity. 
 3. Affirmative Covenants of the Company. The Company hereby covenants and
agrees as follows: 
 3.1 Detailed Financial Information. 

(a) The Company will furnish to each Major Investor (as defined herein) the following reports; provided, that, for the
purposes of this Agreement, “Major Investor” means each Investor who holds not less than 1,400,000 shares of Registrable Securities (as adjusted for stock splits, combinations, reorganizations and the like); provided,
however, that no holder of Series B-2 Preferred Stock or Series B-3 Preferred Stock shall be considered a Major Investor for the purposes of this Agreement: 
 (i) Within twenty (20) days after the end of each calendar month (and for those calendar months that are the last month of the Company’s fiscal quarter), an unaudited consolidated balance sheet
of the Company, as of the end of each such month, or quarter as appropriate, and unaudited consolidated statements of income and cash flows of the Company (each with a comparison to the Company’s budget), for such period, prepared in accordance
with U.S. generally accepted accounting principles (except for the omission of footnotes) consistently applied, subject to changes resulting from normal year-end audit adjustments, and signed by the senior financial officer of the Company.

 (ii) Within twenty (20) days after the end of each fiscal quarter, a summary capitalization table including all shares,
option, warrant, and debt holders and the amount of securities and debt held by each holder. 

  
 19 

 (iii) Within twenty (20) days prior to the start of each new fiscal year, a budget and
summary operating plan for the fiscal year that has been approved by the Board of Directors. 
 (b) The Company will furnish to
GSK, so long as GSK holds shares of Series B-2 Preferred Stock or shares of Series B-3 Preferred Stock, the following reports: 

(i) Within twenty (20) days after the end of each of the Company’s fiscal quarter, an unaudited consolidated balance sheet of
the Company, as of the end of such quarter, and unaudited consolidated statements of income and cash flows of the Company, for such period, prepared in accordance with U.S. generally accepted accounting principles (except for the omission of
footnotes) consistently applied, subject to changes resulting from normal year-end audit adjustments, and signed by the senior financial officer of the Company. 
 (ii) Within twenty (20) days after the end of each fiscal quarter, a summary capitalization table including all shares, option, warrant, and debt holders and the amount of securities and debt held by
each holder. 
 3.2 Annual Financial Statements. The Company will furnish to each Investor, within one hundred
twenty (120) days after fiscal year end (subject to extension to one hundred and eighty (180) days by the approval of a majority of the Board of Directors, an audited consolidated balance sheet of the Company as at the end of such fiscal
year, and audited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared by a nationally recognized accounting firm in accordance with U.S. generally accepted accounting principles
consistently applied. 
 3.3 Company Confidential Information. Each Investor agrees to hold in confidence and
trust and not to misuse or disclose any confidential information provided pursuant to this Section 3. The Company shall not be required to comply with this Section 3 in respect of any Investor whom the Company reasonably determines to be a
competitor or an officer, employee, director, or greater than ten percent (10%) stockholder of a competitor; GSK acknowledges that it is a competitor for purposes of this Section 3 and the Company shall not be required to provide any
sensitive or competitive information to GSK pursuant to this Agreement. 
 3.4 Inspection. The Company shall
permit each Major Investor (except for a Holder reasonably deemed by the Company to be a competitor of the Company), at such Holder’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and
to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this
Section 3.4 to provide access to any information which it reasonably considers to be a trade secret. 
 3.5 Observer
Rights. 
 (a) Dr. Michael Clarke (“Dr. Clarke”) shall be entitled to notice of, to attend
and to any documentation distributed to members before, during or after, all regular meetings of 

  
 20 

 
the Board of Directors (excluding all executive sessions and committee meetings thereof). Notwithstanding the foregoing, the Company reserves the right to withhold any information and to exclude
Dr. Clarke from any such regular meeting or portion thereof (so long as the Company notifies Dr. Clarke of such withholding and of any action taken by the Board of Directors as a result of such meeting) if access to such information or
attendance at such meeting would, (a) in the judgment of the Company’s outside counsel, adversely affect the attorney-client privilege between the Company and its counsel or cause the Board of Directors to breach its fiduciary duties, or
(b) in the good faith determination of the Board of Directors, involve a conflict of interest; provided, however, that if the Consulting Agreement, dated as of August 18, 2004, as amended effective as of November 1,
2005, is terminated for any reason, then the Company reserves the right to withhold any information and to exclude Dr. Clarke from any such regular meeting or portion thereof (so long as the Company notifies Dr. Clarke of such withholding
and of any action taken by the Board of Directors as a result of such meeting) if access to such information or attendance at such meeting would, in the good faith determination of the Board of Directors, result in the disclosure of proprietary
information regarding the Company’s intellectual property rights, the disclosure of which would have an adverse effect on the Company. The Company will use its commercially reasonable efforts to ensure that any withholding of information or any
restriction on attendance is limited only to the extent necessary as set forth in the preceding sentence. Dr. Clarke shall not be (y) permitted to vote at any meeting of the Board, or (z) counted for purposes of determining whether or
not there is sufficient quorum for the Board of Directors to conduct its business. Dr. Clarke shall hold all information received pursuant to this Agreement in the strictest confidence and trust, shall act in a fiduciary manner with respect to
all information so provided, and shall not disclose the same to any third party nor use the same for any purpose. The Company shall not be obligated to reimburse any expenses incurred by Dr. Clarke in attending regular meetings of the Board.

 (b) For so long as the Series B-1 Director nominated by Nomura pursuant to that certain Amended and Restated Voting Agreement
(the “Voting Agreement”) between the Company and certain Investors of approximately even date herewith is not an employee of Nomura or an employee of an Affiliate of Nomura, Nomura shall be entitled to appoint one of its
employees or an employee of one of its Affiliates (as defined in Section 4.2) to serve as a board observer in a non-voting capacity (the “Nomura Board Observer”). The Nomura Board Observer shall be entitled to receive
notice of, to attend and to any documentation distributed to members before, during or after, all regular meetings of the Board of Directors (excluding all executive sessions and committee meetings thereof) at the same time as such materials are
provided to the other Board members. Notwithstanding the foregoing, the Company reserves the right to withhold any information and to exclude the Nomura Board Observer from any such regular meeting or portion thereof (so long as the Company notifies
the Nomura Board Observer of such withholding and of any action taken by the Board of Directors as a result of such meeting) if access to such information or attendance at such meeting would, (a) in the judgment of the Company’s outside
counsel, adversely affect the attorney-client privilege between the Company and its counsel or cause the Board of Directors to breach its fiduciary duties, (b) in the good faith determination of the Board of Directors, involve a direct conflict
of interest (over and above any conflicts of similar investor nominated directors), or (c) result in the disclosure of trade secrets. The Nomura Board Observer shall not be (y) permitted to vote at any meeting of the Board, or
(z) counted for purposes of determining whether or not there is sufficient quorum 

  
 21 

 
for the Board of Directors to conduct its business. The Nomura Board Observer shall hold all information received pursuant to this Agreement in the strictest confidence and trust, shall act in a
fiduciary manner with respect to all information so provided, and shall not disclose the same to any third party nor use the same for any purpose. The Company shall not be obligated to reimburse any expenses incurred by the Nomura Board Observer in
attending regular meetings of the Board. A duplicate copy of all information provided to the director designated by Nomura pursuant to the Voting Agreement shall be provided concurrently to Nomura to the person and using the contact information
provided pursuant to Section 4.4. Nomura shall hold all information received pursuant to this Agreement in the strictest confidence and trust, shall act in a fiduciary manner with respect to all information so provided, and shall not disclose
the same to any third party nor use the same for any purpose. 
 3.6 Directors’ Compensation. The Company
shall provide competitive compensation and shall reimburse the reasonable out-of-pocket expenses incurred to attend meetings of the Board or any committee thereof by non-employee industry executive Board members. In addition, the Company shall
reimburse the reasonable out of pocket expenses incurred to attend meetings or any committee thereof by all other Board members. 
 3.7 Investors’ Counsel Expenses. The Company shall pay or promptly reimburse the reasonable legal fees and expenses of the Investors (a) up to $5,000 in the aggregate in each
future financing of the Company, so long as gross proceeds to the Company from such future financing are greater than or equal to $1,000,000, and (b) up to $30,000 in the aggregate, in the case of a merger or sale of the Company prior to the
IPO. 
 3.8 Option Pool Increase. The Investors acknowledge that, within ninety (90) days of the date hereof,
the Board of Directors or the Compensation Committee thereof may determine, based on management’s input, an appropriate increase to the number of shares of Common Stock available for issuance pursuant to the Company’s Stock Incentive Plan
(the “Plan”), and, if the Board approves such an increase (which will not cause the total number of shares available for the Plan to exceed fifteen percent (15%) of the total share capital of the Company on a fully diluted basis), the
Company and the Investors shall undertake all necessary and appropriate actions to increase the number of shares of Common Stock available for issuance under the Company’s Stock Incentive Plan by such an amount as determined by the Board of
Directors or the Compensation Committee thereof, including the timely delivery of a written consent voting such Investor’s shares of capital stock of the Company in favor of such increase. 

3.9 Qualified Small Business Stock Reports. The Company shall submit to its stockholders (including the Investors) and
to the Internal Revenue Service any reports that may be required under section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. 
 3.10 Director and Officer Insurance. Within ninety (90) days from the Closing (as defined in the Purchase Agreement), the Company will use its commercially reasonable efforts to obtain
and maintain on an annual basis Director and Officer insurance at a level that its Board of Directors deems reasonable and appropriate for the Company. 

  
 22 

 3.11 Waiver of Adjustments. In the event that the Company proposes to sell
shares of its capital stock in a financing at a price per share less than the conversion price of the Series B-2 Preferred Stock then in effect (currently $2.13 per share), GSK may, but shall have no obligation to, consider, on a case by case basis,
at its sole discretion, to reduce its Series B-2 Preferred conversion price to be equal to the then current Series B-1 Preferred conversion price (currently $1.70 per share) such that the Series B-2 Preferred anti-dilution adjustment will be
affected the same as Series B-1 Preferred anti-dilution adjustment in such financing. 
 3.12 Termination of
Covenants. All covenants of the Company set forth in Section 3 of this Agreement shall terminate and be of no further force or effect upon the earlier to occur of (a) the consummation of the Company’s IPO; (b) the
acquisition of the Company by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger, or consolidation), provided that the Company’s stockholders of record as constituted
immediately prior to such transaction hold less than 50% of the voting power of the surviving or acquiring entity; or (c) the date on which the Company is required to file reports with the Commission pursuant to Section 13 or 15(d) of the
Exchange Act. 
  

	 	4.	Miscellaneous. 

4.1 Governing Law. This Agreement shall be governed in all respects by the internal laws of the State of California as
applied to agreements to be performed entirely within California, without regard to choice of laws or conflict of laws provisions thereof. 
 4.2 Successors and Assigns. Except as otherwise specifically set forth in this Agreement, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns,
heirs, executors, and administrators of the parties hereto. Nomura may assign, in whole or in part, its rights and delegate its obligations under this Agreement to any of its Affiliates (which shall include any entity managed or controlled directly
or indirectly by Nomura Holdings, Inc.) or to a fund managed by any of such Affiliates. For purposes of this Agreement, the term “Affiliates” shall have the meaning set forth in Rule 501(b) of Regulation D under the
Securities Act. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided by this Agreement. 
 4.3 Entire Agreement. This Agreement and the
exhibits hereto constitute the full and entire understanding and agreements between the parties with regard to the subjects hereof. Without limiting the generality of the foregoing, this Agreement replaces and supersedes in its entirety the Prior
Agreement. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought,
unless otherwise provided. 
 4.4 Notices, Etc. All notices and other communications required or permitted
hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand, by messenger, by commercial overnight

  
 23 

 
courier (e.g., FedEx), or by confirmed facsimile, addressed (a) if to an Investor, at such Investor’s address set forth the signature pages of this Agreement, or at such other address
as such Investor shall have furnished to the Company in writing, or (c) if to the Company, at its address set forth on the signature page of this Agreement addressed to the attention of the Chief Executive Officer, or at such other address as
the Company shall have furnished to the Investors, with a copy to Mark Roeder, Esq., Latham & Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, facsimile: (650) 463-2600. Unless specifically stated otherwise, each such notice
or other communication shall, for all purposes of this Agreement, be treated as follows: (a) if provided by mail, it shall be deemed to be delivered upon proper deposit in a mailbox, (b) if provided by facsimile, it shall be deemed to be
delivered upon receipt by the sender of confirmation of facsimile transmission, (c) if delivered by hand or by messenger, it shall be deemed to be delivered upon actual delivery, and (d) if delivered via commercial overnight courier
service, the next business day following pre-paid deposit for next business day delivery with such service. In the event of any conflict between the Company’s books and records and this Agreement or any notice delivered hereunder, the
Company’s books and records will control absent fraud or error. 
 4.5 Delays or Omissions. No delay or
omission to exercise any right, power, or remedy accruing to any party upon any breach or default of another party under this Agreement shall impair any such right, power or remedy of such party, nor shall it be construed to be a waiver of any such
breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in
writing and shall be effective only to the extent specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 4.6 Dispute Resolution Fees. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and disbursements in addition to any other relief to which such party may be entitled. 

4.7 Counterparts. This Agreement may be executed in any number of counterparts and signatures may be delivered by
facsimile, each of which may be executed by less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

4.8 Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable or void, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then portions of such provision, or such
provision in its entirety, to the extent necessary, shall be severed from this Agreement and 

  
 24 

 
the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

4.9 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto. 

4.10 Amendment and Waiver. Any provision of this Agreement may be amended or waived (either generally or in a particular
instance and either retroactively or prospectively) with the written consent of the Company, the holders of at least sixty-six and two-thirds percent (66 2/3%) of the then outstanding Registrable Securities held by the Investors, not including those
shares of Registrable Securities held by GSK; provided, for the avoidance of doubt, that the Registrable Securities held by GSK shall not be factored into the numerator or denominator used to calculate the percentage required for an amendment
or waiver (either generally or in a particular instance and either retroactively or prospectively) pursuant to this Section 4.10; provided that no such amendment or waiver shall adversely affect any Investor in a different or
disproportionate manner relative to the other Investors of the same class or series unless such amendment is agreed to in writing by such adversely affected Investor. Any amendment or waiver effected in accordance with this paragraph shall be
binding upon each Investor and the Company. In addition, the Company may waive performance of any obligation owing to it, as to some or all of the Investors, or agree to accept alternatives to such performance, without obtaining the consent of any
Investor. 
 4.11 Effect of Amendment or Waiver. The Investors and their successors and assigns acknowledge that
by the operation of Section 4.10 hereof Investors holding at least sixty-six and two-thirds percent (66 2/3%) of the then outstanding Registrable Securities held by the Investors, not including those shares of Registrable Securities held by
GSK, acting in conjunction with the Company, will have the right and power to diminish or eliminate any or all rights pursuant to this Agreement. 
 4.12 Aggregation of Stock. All shares of Preferred Stock and Common Stock of the Company held or acquired by affiliated entities or persons shall be aggregated for the purpose of determining
the availability of any rights under this Agreement. 
 4.13 Publicity. If the Company desires to issue a press
release or make a public statement or announcement disclosing Genentech, Inc.’s (“Genentech”) investment in the Company or otherwise using Genentech’s name, it must first obtain Genentech’s written approval of
the proposed release or announcement. The Company shall provide Genentech with no less than five business days to review and provide comment regarding any such proposed press release or publicity unless a shorter review time is agreed to by both
parties. 
 4.14 Termination of Prior Agreement. Upon execution hereof by (a) the Company and (b) the
holders of at least sixty-six and two-thirds percent (66 2/3%) of the then outstanding Registrable Securities held by the Investors (as defined in the Prior Agreement), 

  
 25 

 
this Agreement shall supersede the Prior Agreement in its entirety, and the Prior Agreement shall be rendered void. 
 [REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights
Agreement as of the date first above written. 
  

					
	 COMPANY:
  

ONCOMED PHARMACEUTICALS, INC.

		
	By: 	 	/s/ Paul J. Hastings
		 	Name:	 	Paul J. Hastings
		 	Its:	 	President and Chief Executive Officer
		
	Address:	 	
	
	 OncoMed Pharmaceuticals, Inc.
 800 Chesapeake Drive
 Redwood City, CA, 94063

Attention: Paul Hastings, Chief Executive Officer

Facsimile: (650) 298-8600

 
			
	 INVESTORS:
  

ADAMS STREET V, L.P.

		
	By:	 	Adams Street Partners, LLC, its General Partner
		
	By: 	 	/s/ Terry Gould
		 	Name Terry Gould
		 	Title Partner
	
	Address:
	
	 FOR STOCK CERTIFICATES ONLY:
 First Republic Trust Company
 Attention: Tina Barton

Re: 0081
 1230 Avenue of the Americas

2nd Floor
 New York, NY 10020

 
 ALL OTHER CORRESPONDENCE:
 Adams Street V, L.P.
 c/o Adams Street Partners, LLC

One North Wacker Drive, Suite 2200
 Chicago, IL
60606-2807
 Attn: Sejal Shah
 Ph#
(312) 553-7885

 
			
	ADAMS STREET 2006 DIRECT FUND, L.P.
		
	By:	 	ASP 2006 Direct Management, LLC, its General Partner
		
	By:	 	Adams Street Partners, LLC, its Managing Member
		
	By: 	 	/s/ Terry Gould
		 	Name Terry Gould
		 	Title: Partner
	
	Address:
	
	 FOR STOCK CERTIFICATES ONLY:
 First Republic Trust Company
 Attention: Tina Barton

Re: 0082
 1230 Avenue of the Americas

2nd Floor
 New York, NY 10020

 
 ALL OTHER CORRESPONDENCE:
 Adams Street 2006 Direct Fund, L.P.
 c/o Adams Street Partners, LLC

One North Wacker Drive, Suite 2200
 Chicago, IL
60606-2807
 Attn: Sejal Shah
 Ph#
(312) 553-7885

 
			
	BAY PARTNERS XI, L.P.
		
	By:	 	Bay Management Company XI, LLC
	Its:	 	General Partner
	
	/s/ Atul Kapadia
	Name: Atul Kapadia
	Title: Manager
	
	BAY PARTNERS XI PARALLEL FUND, L.P.
		
	By:	 	Bay Management Company XI, LLC
	Its:	 	General Partner
	
	/s/ Atul Kapadia
	Name: Atul Kapadia
	Title: Manager

 
			
	DE NOVO VENTURES II, L.P.
		
	By:	 	De Novo Management II, LLC
	Its:	 	General Partner
	
	/s/ Frederick J. Dotzler
	Name: Frederick J. Dotzler
	Title: Managing Director

 
			
	DELPHI VENTURES VIII, L.P.
		
	By:	 	Delphi Management Partners VIII, LLC
	
	/s/ Deepa R. Pakianathan
	Name:	 	Deepika R. Pakianathan
	Title:	 	Managing Member
	
	Address:
	
	 3000 Sand Hill Road, 1-1135
 Menlo Park, California 94025

	
	DELPHI BIOINVESTMENTS VIII, L.P.
		
	By:	 	Delphi Management Partners VIII, LLC
	
	/s/ Deepa R. Pakianathan
	Name:	 	Deepika R. Pakianathan
	Title:	 	Managing Member
	
	Address:
	
	 3000 Sand Hill Road, 1-1135
 Menlo Park, California 94025

 
			
	/s/ Edward Giles
	EDWARD GILES
		
	Address:	 	 [Address]

 
			
	/s/ Paul J. Hastings
	PAUL J. HASTINGS
		
	Address:	 	

 
			
	/s/ Tim Hoey
	TIM HOEY
		
	Address:	 	 c/o OncoMed Pharmaceuticals, Inc.
 800 Chesapeake Dr.
 Redwood City, CA 94063

 
			
	/s/ Charles F. Hoyng
	CHARLES F. HOYNG
		
	Address:	 	 Latham & Watkins LLP

Attn: Charles F. Hoyng
 140 Scott
Drive
 Menlo Park, CA 94025
  

Fax: (650) 463-2600

 
					
	INVESTOR:	 	
			
		 	By:	 	/s/ Jorge and Sandra Goldstein
		 	Print Name(s): 	 	Jorge and Sandra Goldstein
			
		 	Address:	 	
		
		 	[Address]
		 	 
		 	 
		 	 

							
		 		 	LATTERELL VENTURE PARTNERS, L.P.
		 		 	
		 		 	By:	 	Latterell Capital Management, L.L.C.
		 		 	Its:	 	General Partner
				
		 		 	By:	 	/s/ Patrick F. Latterell
		 		 	Name:	 	Patrick F. Latterell
		 		 	Its:	 	Managing Member
		 		 		 	
		 		 	LATTERELL VENTURE PARTNERS II, L.P.
		 		 	
		 		 	By:	 	Latterell Capital Management II, L.L.C.
		 		 	Its:	 	General Partner
		 		 		 	
		 		 	By:	 	/s/ Patrick F. Latterell
		 		 	Name:	 	Patrick F. Latterell
		 		 	Its:	 	Managing Member
		 		 		 	
		 		 	LATTERELL VENTURE PARTNERS III, L.P.
		 		 	
		 		 	By:	 	Latterell Capital Management III, L.L.C.
		 		 	Its:	 	General Partner
		 		 		 	
		 		 	By:	 	/s/ Patrick F. Latterell
		 		 	Name:	 	Patrick F. Latterell
		 		 	Its:	 	Managing Member
		 		 		 	
		 		 	LVP ASSOCIATES, L.P.
		 		 	
		 		 	By:	 	Latterell Capital Management III, L.L.C.
		 		 	Its:	 	General Partner
		 		 		 	
		 		 	By:	 	/s/ Patrick F. Latterell
		 		 	Name:	 	Patrick F. Latterell
		 		 	Its:	 	Managing Member
		 		 		 	
		 		 	LVP III PARTNERS, L.P.
		 		 	
		 		 	By:	 	Latterell Capital Management III, L.L.C.
		 		 	Its:	 	General Partner
		 		 		 	
		 		 	By:	 	/s/ Patrick F. Latterell
		 		 	Name:	 	Patrick F. Latterell
		 		 	Its:	 	Managing Member
		 		 		 	
		 		 	Address:	 	        One Embarcadero Center, Suite 4050
		 		 		 	        San Francisco, CA 94111

							
		 		 	
				
		 		 		 	/s/ John Lewicki
		 		 		 	JOHN LEWICKI
		 		 		 	
		 		 		 	Address:

							
		 		 	MENDELSON FAMILY TRUST
				
		 		 	By:	 	/s/ Alan C. Mendelson
		 		 	Name:	 	Alan C. Mendelson
		 		 	Title:	 	Trustee
		 		 		 	
		 		 	Address:	 	[Address]
		 		 		 	

							
		 		 	MORGENTHALER PARTNERS VII, L.P.
		 		 	
		 		 	By:	 	Morgenthaler Management Partners VII, LLC
		 		 	Its:	 	Managing Partner
		 		 		 	
		 		 	By:	 	/s/ James Broderick
		 		 	Name:	 	James W. Broderick
		 		 	Title:	 	Managing Member
		 		 		 	
		 		 	Address:	 	    2710 Sand Hill Road
		 		 		 	    Suite 100
		 		 		 	    Menlo Park, CA 94025

	
	/s/ Michael Mulkerrin
	MICHAEL MULKERRIN
	
	Address:

					
		 		 	NOMURA EUROPEAN INVESTMENT LIMITED
	EXECUTED as a DEED by Denise	 	)	 	
	Pollard-Knight as attorney for	 	)	 	
	NOMURA EUROPEAN INVESTMENT	 	)	 	/s/ Denise Pollard-Knight
	LIMITED under a power of attorney	 	)	 	Denise Pollard-Knight as attorney for NOMURA
	dated 7 August 2008	 	)	 	EUROPEAN INVESTMENT LIMITED

 in the presence of: 
  

					
	Name of Witness:	  	M. Couper	  	
	Signature of Witness:	  	/s/ M. Couper	  	
	Address of Witness:	  	 	  	
		  	 	  	
		  	 	  	

 
			
	/s/ Mark Roeder
	MARK V. ROEDER
		
	Address:	 	 Latham & Watkins LLP

Attn: Mark V. Roeder
 140 Scott Drive

Menlo Park, CA 94025

		
		 	Fax: (650) 463-2600

 
			
	SMITHKLINE BEECHAM CORPORATION
		
	By:	 	/s/ Carol Ashe
	Name:	 	Carol Ashe
	Title:	 	Vice President & Secretary
	
	 Attention: Corporate Secretariat

SmithKline Beecham Corporation

One Franklin Plaza (FP2355)

200 N. 16th Street

Philadelphia, PA 19102

Telephone: 215-751-7657

Facsimile: 215-751-5349

	
	 With a copy to:

	
	 Attention: Vice President, Legal Operations (Corporate Functions – US)

GlaxoSmithKline
 One Franklin Plaza (FP2355)
 200 N. 16th Street

Philadelphia, PA 19102

Telephone: 215-751-4172

Facsimile: 215-751-5349

							
		 	INVESTOR:
				
		 		 	By:	 	/s/ Robert Sokohl
		 		 	Print Name(s):	 	Robert Sokohl
				
		 		 	Address:	 	[Address]

			
	 STEVEN AND CYNTHIA BENNER REVOCABLE
 TRUST

		
	By:	 	/s/ Steven Benner
	Name:	 	Steven Benner
	Title:	 	Trustee
		
	Address:	 	 c/o OncoMed Pharmaceuticals, Inc.
 800 Chesapeake Drive
 Redwood City, CA 94063

 
	
	
	/s/ Matthew Strobeck
	MATTHEW STROBECK
	
	Address:
	
	 
	
	 
	
	 

 
			
	INVESTOR:
		
	By:	 	/s/ Michael B Ray 10/17/08 Karen A Ray (10/17/08)
	Print Name(s):	 	Michael B. Ray / Karen A. Ray
		
	Address:	 	[Address]

 
			
	TRIPLEPOINT CAPITAL LLC
		
	By:	 	
	Its:	 	
	
	/s/ Jim Labe
	Name: Jim Labe
	Title: CEO

 
			
	 U.S. VENTURE PARTNERS VIII, L.P.
 USVP VIII AFFILIATES FUND, L.P.
 USVP ENTREPRENEUR PARTNERS VIII-A, L.P.

USVP ENTREPRENEUR PARTNERS VIII-B, L.P.

		
	By:	 	Presidio Management Group VIII, L.L.C.
	Its:	 	General Partner
		
	By:	 	/s/ Michael Maher
	Name:	 	Michael P. Maher
	Its:	 	Attorney-In-Fact
		
	Address:	 	2735 Sand Hill Road
		 	 Menlo Park, CA 94025
 Fax:
(650) 854-3018

 
			
	VERTICAL FUND I, L.P.
		
	By:	 	The Vertical Group, L.P.
	Its:	 	General Partner
		
	By:	 	The Vertical Group GPHC, LLC
	Its:	 	General Partner
		
	By:	 	/s/ John E. Runnells
	Name:	 	John E. Runnells
	Its:	 	General Partner

  

			
	VERTICAL FUND II, L.P.
		
	By:	 	The Vertical Group, L.P.
	Its:	 	General Partner
		
	By:	 	The Vertical Group GPHC, LLC
	Its:	 	General Partner
		
	By:	 	/s/ John E. Runnells
	Name:	 	John E. Runnells
	Its:	 	General Partner
		
	Address:	 	25 DeForest Avenue
		 	Summit, NJ 07901
		 	Attn: John E. Runnells

 
			
	VP COMPANY INVESTMENTS 2008, LLC
	
	VP COMPANY INVESTMENTS 2004, LLC
		
	By:	 	/s/ Alan C. Mendelson
	Name:	 	Alan Mendelson
	Title:	 	Managing Member
		
	Address:	 	c/o Chief Financial Officer
		 	555 West Fifth Street, Suite 800
		 	Los Angeles, CA 90013-1010
	
	Fax: (213) 891-7123

			
	 WILLIAM AND KATHERINE WADDILL TRUST
 DATED JULY 26, 2006

		
	By:	 	/s/ William Waddill
	Name:	 	William D. Waddill
	Title:	 	Trustee
		
	Address:	 	[Address]

 
			
	
	            /s/ James N.
Woody            
	JAMES N. WOODY, M.D., PH.D.
		
	Address:	 	[Address]

 EXHIBIT A 
 INVESTORS 

	
	Adams Street V, L.P.
	Adams Street 2006 Direct Fund, L.P.
	Latterell Venture Partners, L.P.
	Latterell Venture Partners II, L.P.
	Latterell Venture Partners III, L.P.
	LVP III Associates, L.P.
	LVP III Partners, L.P.
	U.S. Venture Partners VIII, L.P.
	USVP VIII Affiliates Fund, L.P.
	USVP Entrepreneur Partners VIII-A, L.P.
	USVP Entrepreneur Partners VIII-B, L.P.
	The Vertical Fund I, LP
	The Vertical Fund II, LP
	Edward Giles
	Genentech, Inc.
	Morgenthaler Partners VII, L.P.
	Dr. James N. Woody
	Paul J. Hastings
	Austin Guerney
	John Lewicki
	Tim Hoey
	Martin H. Goldstein
	Mary Jane Bedegi
	VP Company Investments 2008, LLC
	VP Company Investments 2004, LLC
	Mendelson Family Trust
	Charles F. Hoyng
	Mark V. Roeder
	The Board of Trustees of The Leland Stanford Junior University (Daper I)
	Michael F. Clarke
	William and Katherine Waddill trust dated July 26, 2000
	Steven and Cynthia Benner Revocable Trust
	Michael Mulkerrin
	De Novo Ventures II, L.P.
	Bay Partners XI, L.P.
	Bay Partners Parallel Fund XI, L.P.
	TriplePoint Capital LLC
	SmithKline Beecham Corporation d/b/a GlaxoSmithKline
	Nomura European Investment Limited
	Jorge Goldstein
	Michael Ray
	Robert Sokohl
	 Matthew Strobeck
 Delphi
Ventures VIII, L.P.
 Delphi BioInvestments VIII, L.P.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]